Section summary and perspectives: Neurodevelopmental disorders and regulation of epigenetic changes

Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders

Volumn , Issue , 2012, Pages 334-338

  Barrett, James E ^a   Coyle, Joseph T ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925675266     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511980053.020     Document Type: Chapter

References (19)

1. Berry-Kravis E, Knox A, Hervey C. 2011. Targeted treatments for fragile X syndrome. J Neurodevelop Disord 3:193–210.
2. Cobb S, Guy J, Bird A. 2010. Reversibility of functional deficits in experimental models of Rett syndrome. Biochem Soc Trans 38:498–506.
3. Csoka AB, Szyf M. 2009. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses 73:770–780.
4. Das I, Reeves RH. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech 2011 4:596–606.
5. Dölen G, Carpenter RL, Ocain TD, Bear MF. 2010. Mechanismbased approaches to treating fragile X. Pharmacol Ther 127:78–93.
6. Eacker SM, Dawson TM, Dawson VL. 2009. Understanding microRNAs in neurodegeneration. Nat Rev Neurosci 10:837–841.
7. Gräff J, Kim D, Dobbin, MM, Tsai LH. 2011. Epigenetic regulation of gene expression in physiological and brain processes. Physiol Rev 91:603–649.
8. Guy J, Gan J, Selfridge J, Cobb S, Bird A. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143–1147.
9. Krueger DD, Bear MF. 2011. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411–429.
10. Levenson JM, O’Riordan KJ, Brown KD et al. 2004. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 279:40545–40559.
11. Mehler MF. 2008. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog Neurobiol 86:305–341.
12. Rossignol DA. 2009. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiat 21:213–236.
13. Russo VEA, Martienssen RA, Riggs AD, 1996. Epigenetic Mechanisms of Gene Regulation. Plainview, NY: Cold Spring Harbor Laboratory Press.
14. Sananbenesi F, Fischer A. 2009. The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biol Chem 390:1145–1153.
15. Schratt G. 2009. microRNAs at the synapse. Nat Rev Neurosci 10:842–849.
16. Szyf M. 2009. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 49:243–263.
17. Waddington CH. 1940. Organizers and Genes. Cambridge: Cambridge University Press.
18. Waddington CH. 1942. Canalization of development and the inheritance of acquired characters. Nature 150:563–565.
19. Xu B, Karayiorgou M, Gogos JA. 2010. MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res 1338:78–88.